Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page
- CheckyesterdayChange DetectedThe page now indicates no further participant recruitment and introduces new user-help sections for reading the study record and joining, along with a revision label; a formatting change to the Intervention/Treatment heading is also applied.SummaryDifference0.4%

- Check8 days agoChange DetectedThe page's revision label was updated from v3.5.4 to v3.5.5, indicating a new version of the page content. This appears to be a metadata/software update that does not change the study details, eligibility, or results.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4. This indicates a new version of the page without changes to the study details.SummaryDifference0.0%

- Check37 days agoChange DetectedA Publications section was added, listing a PubMed citation for Subcutaneous ocrelizumab in multiple sclerosis and noting that these publications are automatically filled from PubMed.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page’s revision/version label has been updated from v3.5.2 to v3.5.3, reflecting a site software release rather than a change to the clinical trial record.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.